

HEADLINES

ARRA Opportunities Continue!

Recently Steven L. Kunkel, Ph.D., Senior Associate Dean for Research, sent an email encouraging faculty to take advantage of ARRA opportunities that have been announced. As in the last few weeks, we expect that more opportunities will be announced and available in the next few weeks. Be sure to watch the UMHS Recovery site for Research for information and updates: (<http://www.med.umich.edu/u/recovery/research>).

Also, stay in contact with your department grant administrator as eRPM is released and routing procedures are adapted to take advantage of some of the NIH opportunities. They will be your main information source on how to handle things administratively for your unit! (See related article on the eRPM release in the "From the Grants Office" section of this newsletter.)

In order to help facilitate your applications, the Grant Review & Analysis Office is available to answer questions and help you sort through the guidelines. We have had several faculty take advantage of this already. Please contact Heather Offhaus (hmill@umich.edu) or Jane Sierra (jmsierra@umich.edu) at 734-763-4272.

New iFeasible Application for Researchers

If you're a researcher/investigator, you can now easily check on the feasibility of a study prior to applying for IRB approval. Previously, you would need to ask MCIT to query the Health System Data Warehouse database and then wait for the information. Now you can do it yourself and obtain results almost instantly with this new application developed by MCIT, called "iFeasible."

Sample size is one of the primary factors that determines the feasibility of a research study, and researchers need to know the number of UMHS patients diagnosed or treated with certain clinical conditions before proceeding. The iFeasible application is a web-based, self-service data query tool that allows users to find out the number of patients from a comprehensive list of diagnoses and procedures used at UMHS, using data from the past ten years. The results are displayed as patient distributions by age group, race, and gender. The application runs on a web browser and does not require the installation of any software. However, in view of the nature of the data, users must register for the service and authenticate whenever they use it. For access to the iFeasible tool, please visit the website (<http://www.med.umich.edu/iFeasible/>). Email questions to (bir-bis-era@med.umich.edu).

BMRC Bridging Support Program for Basic Science Research

Deadline: May 15, 2009

The Medical School's Biomedical Research Council (BMRC) is accepting applications for a competitive Bridging Support Program for Basic Science Research. This program provides support to bridge federally funded basic science research grants with a very strong demonstrated likelihood of continued federal funding pending resubmission. Up to \$40,000 is available to maintain projects for up to one year.

Matching funds from the PI's department are required.

Eligibility is limited to full-time, on-campus instructional and research faculty with primary appointments in the Medical School. Grants to be bridged must reside in the Medical School. Visit (<http://www.med.umich.edu/medschool/research/support/funding/bridging.htm>) for complete details. For questions, call 734-615-8802 or email (BMRCsubmit@umich.edu).

FDA Commissioner's Fellowship Program

Deadline: April 15, 2009

The FDA offers a two-year fellowship program, which provides an opportunity for health professionals and other scientists to receive training and experience at the FDA. The objective of the Commissioner's Fellowship Program is to train a cadre of high accomplished scientists intensively in FDA regulatory science across devices, drugs, biologics, foods, and cosmetics. In addition to classes in each FDA product area, fellows will receive instruction in FDA law, policy and international activities, federal budget process, networking and leadership skills, communication with the public and press, biostatistics, epidemiology, clinical trial design, risk assessment and risk management, and extensive case-based learning classes. In parallel with this didactic training, the fellows, with the guidance of their senior scientist preceptor, will engage in a carefully designed and articulated FDA regulatory science project. This experience can be in a wet lab, with a clinical review or evaluation team, in biostatistics, informatics, epidemiology, risk analysis or another aspect of FDA science.

Applicants must have a Doctoral level degree (M.D., D.O., D.V.M., D.D.S., D.P.M., Pharm.D., or Ph.D.) to be eligible. Applicants with a Bachelor's degree in an engineering discipline will also be considered. Applicants must be U.S. citizens, non-citizen nationals of the U.S., or have been admitted to the U.S. for permanent residence before the program start date. Applicants cannot be current FDA employees or FDA contractors (such as ORISE fellows). It is expected that when they have completed their fellowship some fellows will remain at FDA. Others may seek jobs in industry or academia where the knowledge and perspective they gained at FDA will prove invaluable. For more information about the program, visit (<http://www.fda.gov/commissionersfellowships>).

Second Clinical Gene Therapy Trial for Pain Presented

Dr. David Fink, Robert Brear Professor and Chair of the U-M Department of Neurology, presented the protocol for a novel gene therapy for neuropathic pain at the public meeting of the NIH Recombinant DNA Advisory Committee (RAC) on March 3, 2009.

Work by Fink and his collaborators has resulted in the development of a series of gene transfer vehicles (vectors) based on modified Herpes simplex viruses that can be injected into the skin to deliver genes to sensory nerve cells. The first of these vectors, constructed to express the natural opioid peptide enkephalin, is currently in phase 1 clinical trial in patients with pain from cancer at the U-M Cancer Center. The new vector, constructed to cause the release of the inhibitory neurotransmitter gamma amino butyric acid (GABA), is specifically designed to treat pain resulting from nerve damage that occurs in patients with diabetes.

Neuropathic pain is a particularly vexing problem, says Fink. With the best currently available therapies, only one in two patients can expect to achieve a 50 percent reduction in pain. Preclinical studies in animal models demonstrate robust effects from the vector. We are interested to test the therapy now in patients. The trial would be sponsored by Diamyd, a publicly traded Swedish biotechnology company.

Public review by the RAC is the first step in the approval process for novel gene therapies. Fink estimates that the new trial, for patients with pain from diabetic neuropathy, is not likely to be ready for enrollment of the first patients until 2011.

The RAC presentation by Dr. Fink on March 3, 2009 can be viewed at (<http://videocast.nih.gov/PastEvents.asp?c=39>). More information about the research can be found on the Mata-Fink laboratory web site (http://www.med.umich.edu/neurology/mata-fink_lab/).

RESEARCH COMPLIANCE TRAINING AND EDUCATION

Human Research

OHRP Research Community Forum

Reducing Regulatory Burden: Real Strategies for Real Change

Thursday, May 14, 2009

7:00 AM - 5:15 PM

Rackham Building / Michigan League

The federal Office for Human Research Protections (OHRP) and the University of Michigan will be co-hosting a Research Community Forum entitled "Reducing Regulatory Burden: Real Strategies for Real Change" on Thursday, May 14, 2009 at U-M Ann Arbor. This national conference will focus on ways to use the flexibility within human research regulations, proposed changes to the regulations, novel approaches to Institutional Review Board (IRB) activities, and demonstrations on decreasing regulatory burdens for researchers and IRBs. Speakers include federal agency and AAHRPP representatives and experts from academia and private IRBs. The conference is open to the public with a registration fee and co-sponsored by UMMS, MICHR, Michigan State University, Northwestern University, Ohio

State University, Pennsylvania State University, Purdue University, and the St. Joseph Mercy Health System. Full details are posted at (<http://www.research.umich.edu/hrpp/event.html>).

Speak To A Regulatory Specialist (STARS) Program

IRBMED is offering a new service as of February 3, 2009 – the Speak To A Regulatory Specialist (STARS) Program. STARS offers set times during the week when a senior regulatory analyst will be available to speak immediately to callers whose inquiry relates to new or ongoing IRBMED business. STARS will be offered on:

- Tuesdays from 10:00 AM - 12:00 PM
- Wednesdays from 1:00 PM - 3:00 PM

This new program supplements, rather than replaces, researchers' access to IRBMED staff. We still welcome your questions at any time convenient to you, offer consults on new and ongoing research, and educational sessions geared specifically for your needs. If you have any questions, please contact Jan Hewett in the IRBMED office (734-763-4768 or jhewett@umich.edu).

Deception/Incomplete Disclosure Studies

Deception/Incomplete Disclosure Studies: Projects designed to withhold information or provide subjects false information about the research in order to observe the cause of human behavior should undergo careful consideration. The use of deception or incomplete disclosure through an alteration or waiver of documentation is done with the intent to limit information so that subjects do not modify their behavior which could bias data results.

In order to receive a alteration or waiver of informed consent, the Office for Human Research Protections (OHRP) and 45 CFR 46.116 (d) require:

1. The research involves no more than minimal risks to the subjects.
2. The waiver or alteration will not adversely affect the rights and welfare of subjects.
3. The research could not practically be carried out without the waiver or alteration.
4. Whenever appropriate, the subject will be provided with additional pertinent information after participation.

For research projects involving the use of deception/incomplete disclosure, investigators and IRBs need to:

1. Assess the validity of the research.
2. Assess whether or not there are alternate methods to conduct the research.
3. Determine whether or not the project could influence the participants' desire to participate.
4. Describe whether potential harm to the subject through participation can be removed or minimized through debriefing.
5. Address any privacy and confidentiality concerns.

In addition, the IRB examines the research teams' qualification and experience to conduct this type of research or on a specific population by subject screening. With the IRB and study teams working together throughout the complete process, the approval of these specialized studies should be reachable.

References: (http://www.hhs.gov/ohrp/irb/irb_chapter3.htm) and *Institutional Review board: Management and Function*. Bankert and Amdur, editors. 2nd ed., 2006, Chapter 6-5. If you have any questions, please contact Jan Hewett in the IRBMED office (734-763-4768 or jhewett@umich.edu).

Animal Research

Animal Use Protocol Reviews

The UCUCA Office has divided up the protocol reviews to provide better support to our principal investigators (PIs). Four compliance associates are handling administrative review of protocols by PI last name.

First Letter of

PI's Last Name Compliance Associate

A-F	Astrid Haakonstad (astridh@umich.edu)
G-L	Marie Cornell (mhaeussl@umich.edu)
M-R	Sara Waugh (spauly@umich.edu)
S-Z	Matthew Taylor (matttayl@umich.edu)

Feel free to contact your compliance associate directly when working to complete your protocol. Dawn O'Connor, Senior Compliance Associate (oconnord@umich.edu), will continue to oversee all animal facility inspections and the final approval of protocols. In addition, at least once each year, your UCUCA office compliance associates will be visiting with you or your laboratory staff to discuss your approved protocols. During this time, the compliance associate will review your approved protocols with you and provide you with updated information and new policies as it pertains to your laboratory. This is a great opportunity for you to ask any questions you may have about the UCUCA process or policies and regulations.

For additional information about each associate or compliance information, please feel free to visit the UCUCA website (<http://www.ucuca.umich.edu>). If you have any questions or concerns related to animal care at the University, please do not hesitate to contact us at 734-936-8028 or (ucuca.office@umich.edu).

FREQUENTLY ASKED QUESTIONS

The frequently asked questions (FAQs) highlighted here come from a list of FAQs for research maintained by the Office of Research. To see the complete list, visit (<http://www.med.umich.edu/medschool/research/faq.htm>).

Q) Who do I contact if I have questions about recombinant DNA or work with infectious agents?

A) For questions about recombinant DNA, contact the IBC office at 734-936-3934 (jhoats@umich.edu), or the IBC Chair, Philip Hanna (734-615-3706 or pchanna@umich.edu). Answers to many questions may be found on the IBC website (<http://www.research.umich.edu/policies/UM/committees/BRRC/BRRC.html>). For questions about work with infectious agents (non-recombinant) or Select Agents, contact Michael Hanna, Biological Safety Officer (734-647-2318 or mhanna@umich.edu).

Q) How do I obtain training and approval to use hazardous agents?

A) OSEH has developed a number of occupational safety and environmental health programs for the continued safety of all UM employees, to encourage safe practices and strong environmental stewardship, and to remain in compliance with State and federal regulations. For more information, visit the OSEH training webpage (<http://www.osehtraining.umich.edu/osehtraining/>).

FROM THE GRANTS OFFICE

eRPM Is Available!

On March 30, 2009, a campus-wide application for electronic Routing and Proposal Management (eRPM) was released, and MAIS announced the go-live date for eRPM. Selections from the release for tips and training opportunities are included at the bottom of this article.

Faculty will likely find the eRPM system helpful as a central repository of all administrative information around the submission and award of proposals. If you have had a project (as Principal or Participating Investigator identified on the PAF) in the last three years, it will be in the electronic system for viewing. Information available includes: Proposal Approval Form (PAF), Project Award Notices (PAN), and Project Award Changes (PAC). All are attached to the electronic file as viewable PDFs. Then, once the Health System officially "goes live," the system will be used to route and approve projects to external sponsors. (NOTE: The system does not yet "talk" to eResearch Phase I, IRB – that is on tap for a future enhancement.)

The Health System / Medical School has been listed as "going live" for routing on **May 4, 2009**. The convergence of both the ARRA initiatives and eRPM release will make the transition challenging. In an attempt to relieve as much stress and confusion from the routing system as possible, the grant administrators across the school held a discussion and collectively decided to use the system to route proposals electronically after **May 4, 2009**. (This will allow all the NIH Challenge grants, Competitive Revisions, and many of the administrative supplements to be routed on paper without confusing the system with a dual routing path.)

Below is a list of potential activities and appropriate times to use the eRPM system. Hopefully with this built in lead time, the transition from paper to electronics will be as smooth as possible!

- **March 30, 2009** – The system went live (<http://eresearch.umich.edu>).
- **March 30, 2009 and after** – Use the system to look at previous applications, PAN/PAC notices, and to become acquainted with the system.
- **At any point after March 30, 2009** – Begin to build PAFs of projects that will ROUTE May 4, 2009 or after – this includes being able to download Grants.gov forms and prepare them through the system. **NOTE:** If you want to route a project prior to May 4, 2009, you will need to prepare a paper PAF.
- **May 4, 2009** – Route PAFs in the eRPM system.

You are encouraged to use the system and experience it prior to the go-live date in the Health System! In the meantime, if you have any questions, concerns, or implementation questions, please feel free to contact Heather Offhaus (hmills@umich.edu). Watch for further announcements about school-related requirements and materials.

Excerpts from Jim Randolph's MAIS Announcement of eRPM Release

• System Tips:

- Enable pop-ups for eResearch – critical to the proper functioning of the eRPM system.
- To receive email notifications from eResearch, add (eresearch@umich.edu) to your address book/contacts.
- Plain text email users (e.g., Groupwise) turn on the option to view html messages so that links to system are clickable.

• eRPM Training:

To support your use of eRPM, we have a variety of training options.

- Classroom sessions that comprehensively cover PAF creation, the review process, the review routing table, making changes when a PAF is out for review, managing Proposal Data when the proposal is being reviewed, how to review/approve, and PAN/PAC notifications.
- The PAF online course which covers the creation of the PAF.
- Both options, as well as reference material, are available at (<http://www.umich.edu/~eresinfo/erpm/training.html>).

UPDATE FROM WASHINGTON, DC

NIH Begins to Allocate Economic Stimulus Funds

Following signature into law of the American Recovery and Reinvestment Act (ARRA), the National Institutes of Health (NIH) has begun to allocate the \$10.4 billion appropriated to it under the new law. Below is a list of the recent NIH ARRA funding announcements. It is important to note that all information related to ARRA implementation can be found at a new federal website named "recovery.gov." ARRA news specific to NIH can be found at (<http://www.nih.gov/recovery>).

At the start of March 2009, NIH posted the following Requests for Applications (RFAs) and Notices on Challenge Grants, Shared Instrumentation, Facilities Construction, Renovations, Repair and Improvements:

- **RFA-OD-09-003** – Recovery Act Limited Competition: NIH Challenge Grants in Health and Science Research (RC1) (at least \$200 million available): (http://grants.nih.gov/grants/funding/challenge_award/)
- **RFA-RR-09-007** – Recovery Act Limited Competition: Core Facility Renovation, Repair, and Improvement (G20): (<http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-09-007.html>)
- **RFA-RR-09-008** – Recovery Act Limited Competition: Extramural Research Facilities Improvement Program (C06) (\$1 billion available for construction, repair and

renovation of research facilities): (<http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-09-008.html>)

- **PAR-09-118** – Recovery Act Limited Competition: High-End Instrumentation Grant Program (S10): (<http://grants.nih.gov/grants/guide/pa-files/PAR-09-118.html>)
- **NOT-RR-09-008** – Addition of Recovery Funds to the Shared Instrumentation Grant Program (\$300 million available for shared instrumentation and other capital research equipment): (<http://grants.nih.gov/grants/guide/notice-files/NOT-RR-09-008.html>)

EDUCATIONAL OPPORTUNITIES

Annual Biology of Aging Research Retreat

Thursday, May 14, 2009 – 8:30 AM - 4:00 PM

Friday, May 15, 2009 – 8:30 AM - 12:00 PM

Biomedical Science Research Building (BSRB), Room 1150

Sponsored by the University of Michigan Nathan Shock

Center for the Biology of Aging

Internationally known biogerontologists will explore recent, and perhaps pending, discoveries likely to provide new directions and unexpected momentum for research in the biology of aging in the coming five to ten years. Speakers include:

- **Adam Antebi, Ph.D.**, Huffington Center on Aging, Baylor School of Medicine
- **Andrzej Bartke, Ph.D.**, Southern Illinois School of Medicine
- **Matt Kaeberlein, Ph.D.**, University of Washington
- **Richard Loeser, M.D.**, Wake Forest University School of Medicine
- **Daniel Promislow, Ph.D.**, University of Georgia
- **Nicholas Schork, Ph.D.**, Scripps Research Institute
- **Morris White, Ph.D.**, Harvard University

To register or for more information, email Jane Heibel at (jheibel@umich.edu).

44th Graduate Summer Session in Epidemiology

Application Deadline: June 1, 2009

(Applications received by the deadline does not guarantee placement in a course. Enrollment is limited in a number of courses.)

The University of Michigan School of Public Health will offer one-week and three-week courses for all public health professionals and those interested in health research during their 44th Graduate Summer Session in Epidemiology to take place July 12-31, 2009. Topics include: Fundamentals of Biostatistics and Epidemiology, Intermediate Methods, Infectious Diseases, Applied Public Health Practice, Cancer Epidemiology, Clinical Trials, SAS, Logistic Model, Linear Regression, Survival Analysis, Behavioral Change, Social Epidemiology, Longitudinal Studies, Global Health, Pharmacoepidemiology, Surveillance, Multi-level Analysis in Public Health, Scientific Writing, Geographic Information Systems, Health Policy, Environmental and Occupational Epidemiology, Community-Based Research, Evolutionary Epidemiology.

- Distance Learning Courses:
 - Fundamentals in Biostatistics
 - Fundamentals of Epidemiology
- CME credit available

For application and information, visit (<http://www.sph.umich.edu/epid/GSS>). For questions, contact Jody Gray at 734-764-5454 or (umichgss@umich.edu).

FUNDING/AWARD OPPORTUNITIES

Funding opportunities listed below are for external limited submissions and/or opportunities within the University of Michigan only. To search for other funding and recognition opportunities, visit (<http://www.med.umich.edu/medschool/research/support/funding.htm>). This webpage contains a link to M-Quest (a database of opportunities for grants, honors, prizes and fellowships created and maintained by the Office of Research) as well as information on email alert groups.

External Limited Submissions

These are opportunities in which the sponsor has limited the number of proposals allowed from an institution. These competitions require an internal review to select the proposals to submit to the sponsor from the University of Michigan.

Abstracts listed here are general information about these funding programs. We strongly urge interested applicants to visit the listed website to verify complete eligibility, program information, and application procedures before submitting an application.

William T. Grant Scholars Program

Deadline: July 8, 2009

The William T. Grant Scholars Program supports promising early career researchers from various disciplines. The award is intended to facilitate the professional development of early career scholars who have some demonstrated success in conducting high quality research and are seeking to further develop their skills and research program. Studies from these Scholars contribute to theory and policy/practice for improving the lives of young people.

The Foundation supports research to understand and improve the settings of youth ages 8 to 25 in the United States. Important settings include schools, youth-serving organizations, neighborhoods, families, and peer groups.

Candidates are nominated by a supporting institution*** and must submit five-year research plans that demonstrate creativity, intellectual rigor, and a commitment to continued professional development, are grounded in theory and sound scientific methods, and provide evidence for appropriate mentoring from senior investigators. Every year, four to six William T. Grant Scholars are selected and each receives \$350,000 distributed over a five-year period.

The award is designed for early career researchers. Applicants must have received their terminal degree within seven years of submitting their application. The award may not be used as a postdoctoral fellowship. See complete details at (http://www.wtgrantfoundation.org/info-ur15243/info-ur1_show.htm?doc_id=646415).

*** **Only one candidate may be nominated per major division of the university.** For Medical School faculty, please contact Jyoti Athanikar (jnathani@umich.edu or 734-615-1630) at the Office of Research if you intend to apply so that the necessary internal selection process can be established.

• • • Deadline Watch • • •

MICHR / CTSA Pilot and Collaborative Grant Program in Clinical and Translational Research

Deadline: Extended to April 15, 2009

(<http://www.michr.umich.edu/programs/pilot-grant.html>)

Michigan Gastrointestinal Peptide Research Center Pilot Feasibility Projects

Deadline: April 17, 2009

(<http://www.med.umich.edu/mgpc/pilot>)

UM Postdoctoral Translational Scholars Program

Deadline: April 17, 2009

(<http://www.michr.umich.edu/ptsp>)

UMMS AWARDED GRANTS

External Awarded Grants

Anesthesiology

PI: Baghdoyan, Helen

Title: CHOLINERGIC MECHANISMS OF REM SLEEP GENERATION

Sponsor: NIH 4 R37 MH 045361 22

Project Dates and Amount of Award: 03/15/09-01/31/14; \$1,800,519

PI: Harris, Richard

Co-I: Maly Sundgren, Pia (Radiology Department)

Title: DISTINCT ROLES OF ANTERIOR AND POSTERIOR INSULA GLUTAMATE IN CHRONIC PAIN

Sponsor: Dana, Charles A. Foundation

Project Dates and Amount of Award: 01/01/09-12/31/11; \$200,000

Family Medicine

PI: Green, Lee

Co-I: Feters, Michael (Department of Family Medicine) / Nease Jr, Donald (Department of Family Medicine)

Title: RESEARCH PARTNERSHIP WITH A STATE-WIDE NETWORK OF FEDERALLY QUALIFIED HEALTH CENTERS

Sponsor: Westat

Project Dates and Amount of Award: 02/01/09-04/30/09; \$100,000

PI: Klinkman, Michael

Co-I: Sen, Ananda (Ctr Statistical Consul & Res)

Title: ENHANCING THE SUSTAINABILITY OF DEPRESSION DISEASE MANAGEMENT SUPPORT FOR PRIMARY CARE

Sponsor: Flinn, Ethel and James, Foundation

Project Dates and Amount of Award: 01/01/09-12/31/10; \$200,000

Graduate and Postdoctoral Studies / Office of Student Programs

PI: Engelke, David

Co-I: Barald, Kate (MSA PIBS) / Isom, Lori (MSA PIBS)

Title: MICHIGAN POSTBACCALAUREATE RESEARCH EDUCATION PROGRAM

Sponsor: NIH 1 R25 GM 086262 01

Project Dates and Amount of Award: 03/01/09-02/28/13; \$1,108,148

Human Genetics

PI: Lenk, Guy

Title: MECHANISM OF NEURODEGENERATION IN INHERITED PERIPHERAL NEUROPATHY

Sponsor: Hartwell Foundation

Project Dates and Amount of Award: 01/01/09-12/31/10; \$100,000

Internal Medicine

PI: Akin, Cem

Title: RDEA CKIT COMPOUNDS

Sponsor: Ardea Biosciences

Project Dates and Amount of Award: 04/01/09-09/30/09; \$28,612

PI: Anderson, Michelle
Title: NAPS 2 CONTINUATION
Sponsor: NIH - Subcontracts TO University of Pittsburgh R01 DK 061541
Project Dates and Amount of Award: 05/01/08-04/30/09; \$16,112

PI: Baker, Laurence
Title: SORAFENIB PLUS TEMSIROLIMUS OR SORAFENBIN PLUS TIPIFARNIB IN UNTREATED METASTATIC MELANOMA (TASK ORDER 10, 25XS105, S0438: RANDOMIZED PHASE II TRIAL OF)
Sponsor: NIH - Subcontracts TO Science Applications International Corporation SAIC
Project Dates and Amount of Award: 10/01/08-09/25/09; \$50,400

PI: Bixby, Dale
Title: THE MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR RAD001 (EVEROLIMUS) IN COMBINATION WITH IMATINIB (GLEEVEC). AN OPEN LABEL, TIME-TO-EVENT CONTINUOUS REASSESSMENT METHOD, PHASE I/II STUDY OF
Sponsor: American Society of Hematology
Project Dates and Amount of Award: 07/01/08-06/30/09; \$50,000

PI: Collins, Kathleen
Title: MOLECULAR MECHANISMS OF HIV'S IMMUNE EVASION
Sponsor: NIH 2 R01 AI 046998 10 A1
Project Dates and Amount of Award: 04/01/09-03/31/14; \$1,913,735

PI: Conjeevaram, Hari
Title: GS-9450 IN ADULTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) (A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ACTIVITY OF)
Sponsor: Gilead Sciences, Inc. TO PPD, Inc.
Project Dates and Amount of Award: 01/28/09-01/27/10; \$81,692

PI: Grossman, Paul
Title: A COMPARISON OF PRASUGREL AND CLOPIDOGREL IN ACUTE CORONARY SYNDROME (ACS) SUBJECTS WITH UNSTABLE ANGINA/ NON-ST-ELEVATION MYOCARDIAL INFARCTION (UA/NSTEMI) WHO ARE MEDICALLY MANAGED - THE TRILOGY ACS STUDY
Sponsor: Quintiles, Inc. TO Lilly Research Laboratories-Elanco Products Company
Project Dates and Amount of Award: 02/05/09-02/28/11; \$120,394

PI: Hammer, Gary
Title: STAR EXPRESSION: INTEGRATION OF TRANSCRIPTION WITH REGULATION VIA THE 3'UTR
Sponsor: NIH - Subcontracts TO University of Wisconsin R01 DK 074819
Project Dates and Amount of Award: 07/22/08-05/31/09; \$63,750

PI: Kim, Catherine
Co-I: Richardson, Caroline (Department of Family Medicine)
Title: A PILOT LIFESTYLE INTERVENTION FOR WOMEN WITH HISTORIES OF GDM: THE PEG STUDY
Sponsor: NIH 1 R03 DK 083332 01
Project Dates and Amount of Award: 04/01/09-03/31/11; \$154,500

PI: Lawrence, Daniel
Title: TARGETING PLASMINOGEN ACTIVATOR INHIBITOR-1 TO INHIBIT RESTENOSIS
Sponsor: Missouri, State of TO University of Missouri
Project Dates and Amount of Award: 01/01/09-06/30/09; \$120,000

PI: Oral, Hakan
Title: EFFECT OF OMEGA-3 FATTY ACIDS ON SHORT AND LONG-TERM MAINTENANCE OF SINUS RHYTHM AFTER RADIOFREQUENCY CATHETER ABLATION FOR ATRIAL FIBRILLATION
Sponsor: Reliant Pharmaceuticals, Inc
Project Dates and Amount of Award: 02/24/09-12/01/10; \$389,735

PI: Peres, Edward
Title: UMCC 2007.137: TRIAL OF DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION
Sponsor: Otsuka America Pharm, Inc.
Project Dates and Amount of Award: 09/30/08-02/28/13; \$126,800

PI: Phillips, Kristine
Co-I: Schiopu, Elena (Int Med-Rheumatology) / Seibold, James (Int Med-Rheumatology)
Title: AMG 827 IN SUBJECTS WITH RHEUMATOID ARTHRITIS (A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF)
Sponsor: Amgen, Inc.
Project Dates and Amount of Award: 03/03/09-10/30/11; \$283,035

PI: Reddy, Raju
Co-I: Chen, Yuqing (Int Med-Cardiology) / Hershenson, Marc (Pediatrics-Pulmonary Medicine) / Lukacs, Nicholas (Pathology Department)
Title: NITRATED FATTY ACIDS, NOVEL ANTIINFLAMMATORY MEDIATORS IN ALLERGIC AIRWAY DISEASE
Sponsor: NIH 1 R01 HL 093196 01 A1
Project Dates and Amount of Award: 04/01/09-03/31/13; \$1,509,123

PI: Saad, Richard
Title: CTT VALIDATION STUDY PROTOCOL #120508
Sponsor: Smartpill Diagnostics
Project Dates and Amount of Award: 02/01/09-05/31/09; \$90,325

PI: Schuetze, Scott
Title: DENOSUMAB IN SUBJECTS WITH GIANT CELL TUMOR OF BONE (UMCC 2008.081 AN OPEN-LABEL, MULTI-CENTER, PAHSE 2 STUDY OF)
Sponsor: Amgen, Inc.
Project Dates and Amount of Award: 12/05/08-12/04/14; \$50,501

PI: Smerage, Jeffrey
Title: SORAFENIB COMPARED TO PLACEBO WHEN ADMINISTERED IN COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER THAT HAS PROGRESSED DURING OR AFTER BEVACIZUMAB THERAPY (UMCC 2008.044: A DOUBLE-BLIND, RANDOMIZED PHASE 2B STUDY OF)
Sponsor: Bayer Corporation TO Acorn Cardiovascular, Inc.
Project Dates and Amount of Award: 01/28/09-01/27/14; \$404,525

PI: Smith, Jeannina
Co-I: Kaul, Daniel (Int Med-Infectious Diseases) / Riddell Iv, James (Int Med-Infectious Diseases)
Title: A PROSPECTIVE, NON-INTERVENTION, OBSERVATIONAL ASSESSMENT OF THE CORRELATION BETWEEN CIRCULATING BIOMARKERS OF FUNGAL BIOBURDEN AND CLINICAL OUTCOME IN THE SETTING OF INVASIVE ASPERGILLOSIS
Sponsor: Merck and Company, Inc. TO Covance, Inc.
Project Dates and Amount of Award: 01/01/09-12/31/10; \$251,550

PI: Yamazaki, Masatoshi
Title: THREE DIMENSIONAL SCROLL WAVE DYNAMICS DURING CHRONIC ATRIAL FIBRILLATION
Sponsor: Japanese Society of Electrocardiology
Project Dates and Amount of Award: 01/01/09-12/31/09; \$20,000

PI: Zalupski, Mark
Title: SINGLE AGENT LAROTAXEL (XRP9881) COMPARED TO CONTINUOUS ADMINISTRATION OF 5-FU FOR THE TREATMENT OF PATIENTS WITH ADVANCED PANCREATIC CANCER PREVIOUSLY TREATED WITH A GEMCITABINE-CONTAINING REGIMEN (2008.075: A RANDOMIZED, OPEN LABEL MULTI-CENTER STUDY OF)
Sponsor: Sanofi-Aventis Pharmaceuticals
Project Dates and Amount of Award: 02/15/09-02/14/13; \$415,700

PI: Zimmermann, Ellen
Title: GI FELLOW EDUCATION SUPPORT
Sponsor: Centocor, Inc.
Project Dates and Amount of Award: 03/01/09-02/28/10; \$4,500

Medical Education

PI: Tang, Tricia
Co-I: Anderson, Robert (Med Ed/Ofc of Ed Resources&Res) / Funnell, Martha (Med Ed/Ofc of Ed Resources&Res) / Heisler, Mary Ellen (Int Med-General Medicine) / Piette, John (Int Med-General Medicine) / Spencer, Michael (School of Social Work)
Title: PEER-LED SELF-MANAGEMENT SUPPORT IN "REAL-WORLD" CLINICAL AND COMMUNITY SETTINGS
Sponsor: American Academy of Family Physicians
Project Dates and Amount of Award: 02/01/09-09/20/11; \$805,000

Michigan Nanotechnology Institute for Medicine and Biological Sciences

PI: Baker Jr, James
Title: SUPPLEMENT REQUEST TO: DNA-LINKED DENDRIMER NANOPARTICLE SYSTEMS FOR CANCER DIAGNOSIS AND TREATMENT (R01 CA119409)
Sponsor: NIH 3 R01 CA 119409 04 S1
Project Dates and Amount of Award: 08/01/08-07/31/09; \$50,000

Microbiology and Immunology

PI: Ono, Akira
Title: THE ROLE OF PIP2 AS A COFACTOR FOR HIV-1 ASSEMBLY AT THE PLASMA MEMBRANE
Sponsor: Amer. Fdn. For Aids Res.
Project Dates and Amount of Award: 01/01/09-12/31/09; \$120,000

PI: Telesnitsky, Alice
Co-I: King, Steven (Microbiology and Immunology)
Title: NON-VIRAL RNAs IN HIV-1 PARTICLES
Sponsor: NIH 1 R21 AI 080276 01 A2
Project Dates and Amount of Award: 03/01/09-02/28/11; \$424,875

Molecular & Behavioral Neuroscience Institute

PI: Burmeister, Margit
Co-I: Lesperance, Marci (Pediatric Otolaryngology) / Li, Jun (Human Genetics Department)
Title: COMPREHENSIVE GENOMIC APPROACH TO RARE HEARING DISORDERS AND ATAXIA
Sponsor: NIH 1 R21 DC 010074 01
Project Dates and Amount of Award: 02/12/09-01/31/11; \$424,875

Molecular & Integrative Physiology

PI: Omary, Bishr
Title: KERATIN BIOLOGY AND DISEASE ASPECTS IN SIMPLE EPITHELIA
Sponsor: NIH 2 R01 DK 047918 16
Project Dates and Amount of Award: 02/13/09-01/31/14; \$2,271,371

PI: Schnell, Santiago
Title: IBCST-COMPETITIVE RENEWAL OF MSM: MULTISCALE STUDIES OF SEGMENTATION IN VERTEBRATES
Sponsor: NIH - Subcontracts TO Indiana University R01 GM 007669
Project Dates and Amount of Award: 09/01/08-08/31/09; \$60,620

PI: Stuenkel, Edward
Co-I: Ernst, Stephen (Cell and Developmental Biology)
Title: MECHANISMS OF RAB27 REGULATION OF INSULIN SECRETION
Sponsor: NIH 1 R01 DK 077050 01 A2
Project Dates and Amount of Award: 03/01/09-01/31/13; \$1,448,559

Neurology

PI: Brown, Devin
Title: GENE DISCOVERY FOR WARFARIN-RELATED INTRACEREBRAL HEMORRHAGE
Sponsor: NIH - Subcontracts TO Massachusetts General Hospital R01 NS 059727
Project Dates and Amount of Award: 08/01/08-07/31/09; \$9,600

PI: Feldman, Eva
Title: 2009 INTERNATIONAL PERIPHERAL NERVE SOCIETY MEETING AT WUERZBURG, GERMANY
Sponsor: NIH 1 R13 NS 065539 01
Project Dates and Amount of Award: 03/01/09-02/28/10; \$10,000

PI: Segal, Benjamin
Co-I: Mikol, Daniel (Neurology Department) / Srinivasan, Ashok (Radiology Department)
Title: TH 17 POLARIZATION AND TRAFFICKING IN MULTIPLE SCLEROSIS
Sponsor: Dana, Charles A. Foundation
Project Dates and Amount of Award: 10/01/07-09/30/09; \$200,000

Neurosurgery

PI: Keep, Richard
Co-I: Xiang, Jianming (Neurosurgery) / Zochowska, Anuska (Pathology Department)
Title: ENDOGENOUS AND EXOGENOUS PROTECTION OF THE BBB IN STROKE
Sponsor: NIH 2 R01 NS 034709 13 A1
Project Dates and Amount of Award: 02/16/09-01/31/14; \$1,687,008

PI: Lin, Chia-Ying
Co-I: La Marca, Frank (Neurosurgery)
Title: USE EXTERNAL STIMULATOR WITH INTRADISCAL STIMVASTATIN DELIVERY TO FACILITATE CHONDROGENESIS IN INTERVERTEBRAL DISC REPAIR
Sponsor: Biomet, Inc.
Project Dates and Amount of Award: 01/01/09-12/31/09; \$55,948

Obstetrics & Gynecology

PI: Smith, Yolanda
Co-I: Persad, Carol (Psychiatry Department) / Zubieta, Jon (Molecular & Behav Neurosc Inst)
Title: HORMONES AND COGNITIVE PROCESSING IN EARLY POSTMENOPAUSAL WOMEN
Sponsor: NIH 1 R21 AG 031951 01 A1
Project Dates and Amount of Award: 04/01/09-03/31/11; \$361,144

PI: Xu, Xiao
Title: IMPACT OF DRUG INSURANCE OF HEALTH BEHAVIORS AND OUTCOMES AMONG SENIORS
Sponsor: AHRQ TO Wayne State University R01 HS 017414
Project Dates and Amount of Award: 04/01/09-03/31/10; \$22,748

Otolaryngology

PI: Carey, Thomas
Co-I: Bradford, Carol (Otorhinolaryngology Department) / Chepeha, Douglas (Otorhinolaryngology Department) / Cordell, Kitrina (Periodontics and Oral Medicine) / Mchugh, Jonathan (Pathology Department) / Prince, Mark (Otorhinolaryngology Department) / Worden, Francis (Int Med-Hematology/Oncology)
Title: BIOMARKERS TO GUIDE TREATMENT AND IMPROVE SURVIVAL IN ORAL/OROPHARYNGEAL CANCER
Sponsor: NIH 1 R01 DE 019126 01 A1
Project Dates and Amount of Award: 03/02/09-02/28/13; \$1,386,000

Pathology

PI: Dou, Yali
Title: EPIGENETIC REGULATION OF TRANSCRIPTION BY MIXED LINEAGE LEUKEMIA PROTEIN MLL1
Sponsor: NIH 1 R01 GM 082856 01 A2
Project Dates and Amount of Award: 04/01/09-02/28/14; \$1,455,324

PI: Ferguson, David
Title: ROLES OF MRN IN PREVENTING ONCOGENIC TRANSLOCATION IN LEUKEMIA AND LYMPHOMA
Sponsor: Leukemia and Lymphoma Society
Project Dates and Amount of Award: 07/01/09-06/30/14; \$550,000

PI: Lombard, David
Title: SIR2 IN STRESS RESISTANCE, AGING, AND DNA REPAIR
Sponsor: NIH 7 K08 AG 022325 06
Project Dates and Amount of Award: 03/01/09-05/31/09; \$87,480

Pediatrics & Communicable Diseases

PI: Keegan, Catherine
Co-I: Maillard, Ivan (Life Sciences Institute-Admin)
Title: MOUSE MODELS OF GENOMIC INSTABILITY AND BIRTH DEFECTS
Sponsor: NIH 1 R01 HD 058606 01 A1
Project Dates and Amount of Award: 04/01/09-03/31/14; \$1,575,444

PI: LiPuma, John
Co-I: Sajjan, Umadevi (Pediatrics-Pulmonary Medicine)
Title: ROLE OF BURKHOLDERIA CENOCEPACIA ADHESIN, ADHA, IN CYSTIC FIBROSIS INFECTIONS
Sponsor: NIH - Subcontracts TO University of Virginia R21 AI 072679
Project Dates and Amount of Award: 01/07/09-12/31/09; \$54,224

PI: Moler, Frank
Co-I: Charpie, John (Pediatrics-Cardiology) / Silverstein, Faye (Pediatrics-Neurology)
Title: THAPCA TRIALS-SCIENTIFIC APPLICATION
Sponsor: NIH 1 U01 HL 094345 01
Project Dates and Amount of Award: 03/09/09-08/31/09; \$348,665

PI: Nasr, Samya
Co-I: Arteta, Manuel (Pediatrics-Pulmonary Medicine) / Filbrun, Amy (Pediatrics-Pulmonary Medicine) / Lumeng, Carey (Pediatrics-Pulmonary Medicine) / Tsai, Wan (Pediatrics-Pulmonary Medicine)
Title: TWO DOSES OF TIOTROPIUM BROMIDE (2.5 UG AND 5 UG) ADMINISTERED ONCE DAILY VIA THE RESPIMAT DEVICE FOR 12 WEEKS IN PATIENTS WITH CYSTIC FIBROSIS (A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF)
Sponsor: Boehringer Ingelheim, Ltd.
Project Dates and Amount of Award: 01/27/09-01/26/10; \$120,190

PI: Padmanabhan, Vasantha
Title: BISPHENOL-A AND REPRODUCTIVE DYSFUNCTION
Sponsor: NIH 1 R01 ES 016541 01 A1
Project Dates and Amount of Award: 02/11/09-11/30/13; \$2,037,289

Physical Medicine & Rehabilitation

PI: Yarjanian, John
Title: PERCUTANEOUS PLASMA DISCECTOMY FOR TREATMENT OF SYMPTOMATIC CERVICAL, THORACIC AND LUMBAR INTERVERTEBRAL DISCS
Sponsor: ArthroCare Corporation
Project Dates and Amount of Award: 01/01/09-08/30/09; \$30,764

Psychiatry

PI: Arnedt, J Todd

Co-I: Armitage, Roseanne (Psychiatry Depression Center) / Hoffmann, Robert (Psychiatry Depression Center) / Langenecker, Scott (Psychiatry-Neuropsychology) / Young, Elizabeth (Molecular & Behav Neurosc Inst)
Title: REPEATED PARTIAL SLEEP DEPRIVATION TO AUGMENT SSRI RESPONSE IN DEPRESSION

Sponsor: NIH 1 R01 MH 077690 01 A2

Project Dates and Amount of Award: 03/01/09-12/31/13; \$1,738,125

Radiation Oncology

PI: Antonuk, Larry

Title: HIGH RESOLUTION MAMMOGRAPHY SENSOR

Sponsor: NIH - Subcontracts TO Radiation Monitoring Devices, Inc. R43 CA 099104

Project Dates and Amount of Award: 09/01/08-08/31/10; \$64,031

Radiology

PI: Kilbourn, Michael

Title: SYNTHESIS AND BIOLOGICAL EVALUATION OF DERIVATIVES OF DIHYDROTETRABENAZINE STEREOISOMERS

Sponsor: Cambridge Laboratories

Project Dates and Amount of Award: 02/20/09-02/19/10; \$257,340

PI: Luker, Gary

Co-I: Luker, Kathryn (Radiology Department)

Title: IMAGING CXCL12-CXCR4 SIGNALING AND INHIBITION IN OVARIAN CANCER

Sponsor: US DOD-Army, Department of the

Project Dates and Amount of Award: 07/01/09-07/31/12; \$567,982

Surgery

PI: Adepoju, Linda

Title: TLR 8 AS A POTENTIAL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMA

Sponsor: Amer. Medical Association

Project Dates and Amount of Award: 03/01/09-02/28/10; \$2,440

PI: Bolling, Steven

Title: JUICE BLEND CHEMICAL ANALYSIS

Sponsor: Old Orchard Brands, Llc

Project Dates and Amount of Award: 03/15/09-09/15/09; \$6,953

PI: Englesbe, Michael

Co-I: Birkmeyer, John (General Surgery Section) / Merion, Robert (General Surgery Section)

Title: TOWARDS PAY FOR PERFORMANCE IN KIDNEY TRANSPLANTATION

Sponsor: NIH 1 K08 DK 082758 01

Project Dates and Amount of Award: 04/01/09-03/31/14; \$669,600

PI: Liu, Yang

Co-I: Cooney, Kathleen (Int Med-Hematology/Oncology)

Title: FOXP3 AS X-LINKED TUMOR SUPPRESSOR GENE

Sponsor: US DOD-Army, Department of the

Project Dates and Amount of Award: 04/01/09-06/30/12; \$562,200

PI: Lubman, David

Title: SCREENING OF GLYCO-MARKERS OF PANCREATIC CANCER USING A MICRO-ARRAY APPROACH

Sponsor: NIH TO Johns Hopkins University U01 CA 084986

Project Dates and Amount of Award: 01/01/09-12/31/09; \$154,500

PI: Napolitano, Lena

Title: DISSEMINATING ORGANIZATIONAL SBI SERVICES (DO-SBIS) AT TRAUMA CENTERS

Sponsor: NIH - Subcontracts TO University of Washington

Project Dates and Amount of Award: 01/01/09-04/30/12; \$11,000

PI: Pagani, Francis

Co-I: Aaronson, Keith (Int Med-Cardiology)

Title: EVALUATION OF THE HEARTWARE LVAD SYSTEM FOR THE TREATMENT OF ADVANCED HEART FAILURE

Sponsor: Heartware, Inc.

Project Dates and Amount of Award: 01/05/09-12/31/11; \$156,800

UMMS RESEARCH PUBLICATIONS

Biological Chemistry

Lexa KW, Damm KL, Quintero JJ, Gestwicki JE, Carlson HA. Clarifying allosteric control of flap conformations in the 1TW7 crystal structure of HIV-1 protease. *Proteins*. 2009 Mar; 74(4): 872-80.

Rozel S, Galbán CJ, Nicolay K, Lee KC, Sud S, Neeley C, Snyder LA, Chenevert TL, Rehemtulla A, Ross BD, Pienta KJ. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. *J Cell Biochem*. 2009 Mar 3 (Epub ahead of print).

Sarangi R, Dey M, Ragsdale S. Geometric and Electronic Structures of the NiII and Methyl-NiIII Intermediates of Methyl-Coenzyme M Reductase. *Biochemistry*. 2009 Feb 25 (Epub ahead of print).

Wang W, Guan KL. AMPK and Cancer. *Acta Physiol (Oxf)*. 2009 Feb 25 (Epub ahead of print).

Cell & Developmental Biology

Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A, Feldmann G. Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer. *Clin Cancer Res*. 2009 Mar 3 (Epub ahead of print).

Family Medicine

Creswell JW, Fetters MD, Plano-Clark VL, Morales A. Mixed Methods Research for Nursing and the Health Sciences. Andrew S, Halcomb EJ, editors; United Kingdom: Wiley-Blackwell, 2009; pp.161-80, Chapter 9: Mixed methods intervention trials.

Human Genetics

Arlt MF, Mülle JG, Schaibley VM, Ragland RL, Durkin SG, Warren ST, Glover TW. Replication Stress Induces Genome-wide Copy Number Changes in Human Cells that Resemble Polymorphic and Pathogenic Variants. *Am J Hum Genet*. 2009 Feb 18 (Epub ahead of print).

Chen H, Wang N, Burmeister M, McInnis MG. MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. *Int J Neuropsychopharmacol*. 2009 Mar 2: 1-7.

DeGiorgio M, Rosenberg NA. An unbiased estimator of gene diversity in samples containing related individuals. *Mol Biol Evol*. 2009 Mar; 26(3): 501-12.

Hensley Alford S, Schwartz K, Soliman A, Johnson CC, Gruber SB, Merajver SD. Breast cancer characteristics at diagnosis and survival among Arab-American women compared to European- and African-American women. *Breast Cancer Res Treat*. 2009 Mar; 114(2): 339-46.

Hunley KL, Healy ME, Long JC. The global pattern of gene identity variation reveals a history of long-range migrations, bottlenecks, and local mate exchange: Implications for biological race. *Am J Phys Anthropol*. 2009 Feb 18 (Epub ahead of print).

Jester JM, Nigg JT, Puttler LI, Long JC, Fitzgerald HE, Zucker RA. Intergenerational transmission of neuropsychological executive functioning. *Brain Cogn*. 2009 Feb 23 (Epub ahead of print).

Johnsen JM, Teschke M, Pavlidis P, McGee BM, Tautz D, Ginsburg D, Baines JF. Selection on cis-regulatory variation at B4galnt2 and its influence on von Willebrand factor in house mice. *Mol Biol Evol*. 2009 Mar; 26(3): 567-78.

Li MD, Burmeister M. New insights into the genetics of addiction. *Nat Rev Genet*. 2009 Feb 24 (Epub ahead of print).

Long JC, Li J, Healy ME. Human DNA sequences: More variation and less race. *Am J Phys Anthropol*. 2009 Feb 18 (Epub ahead of print).

Papale LA, Beyer B, Jones JM, Sharkey LM, Tufik S, Epstein M, Letts VA, Meisler MH, Frankel WN, Escayg A. Heterozygous mutations of the voltage-gated sodium channel SCN8A are associated with spike-wave discharges and absence epilepsy in mice. *Hum Mol Genet*. 2009 Mar 2 (Epub ahead of print).

Schroeder KB, Jakobsson M, Crawford MH, Schurr TG, Boca SM, Conrad DF, Tito RY, Osipova LP, Tarskaia LA, Zhadanov SI, Wall JD, Pritchard JK, Malhi RS, Smith DG, Rosenberg NA. Haplotypic background of a private allele at high frequency in the Americas. *Mol Biol Evol*. 2009 Feb 17 (Epub ahead of print).

Sharkey LM, Cheng X, Drews V, Buchner DA, Jones JM, Justice MJ, Waxman SG, Dib-Hajj SD, Meisler MH. The ataxia3 Mutation in the N-Terminal Cytoplasmic Domain of Sodium Channel Nav1.6 Disrupts Intracellular Trafficking. *J Neurosci*. 2009 Mar 4; 29(9): 2733-2741.

Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature*. 2009 Feb 12; 457(7231): 910-4.

Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M, Simeone DM. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. *Cancer Cell*. 2009 Mar 3; 15(3): 207-19.

Internal Medicine

Infectious Diseases:

Cooke DT, Pagani FD, Kaul DR, Cooke KR, Lau CL, Riddell J 4th. Successful treatment of pulmonary zygomyces in two transplant recipients with liposomal amphotericin B and partial surgical resection followed by posaconazole. *Mycoses*. 2009 Jan 9 (Epub ahead of print).

Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009, 48(5): 503-535.

Microbiology and Immunology

Abend JR, Joseph AE, Das D, Campbell-Cecen DB, Imperiale MJ. A truncated T antigen expressed from an alternatively spliced BK virus early mRNA. *J Gen Virol*. 2009 Mar 4 (Epub ahead of print).

Breinich MS, Ferguson DJ, Foth BJ, van Dooren GG, Lebrun M, Quon DV, Striepen B, Bradley PJ, Frischknecht F, Carruthers VB, Meissner M. A dynamin is required for the biogenesis of secretory organelles in *Toxoplasma gondii*. *Curr Biol*. 2009 Feb 24; 19(4): 277-86.

Huynh MH, Carruthers VB. Tagging of endogenous genes in a *Toxoplasma gondii* strain lacking Ku80. *Eukaryot Cell*. 2009 Feb 13 (Epub ahead of print).

Lybarger SR, Johnson TL, Gray MD, Sikora AE, Sandkvist M. Docking and assembly of the type II secretion complex of *Vibrio cholerae*. *J Bacteriol*. 2009 Feb 27 (Epub ahead of print).

Osterholzer JJ, Surana R, Milam JE, Montano GT, Chen GH, Sonstein J, Curtis JL, Huffnagle GB, Toews GB, Olszewski MA. Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. *Am J Pathol*. 2009 Mar; 174(3): 932-43.

Peng W, Peltier DC, Larsen MJ, Kirchhoff PD, Larsen SD, Neubig RR, Miller DJ. Identification of Thieno[3,2-b]Pyrrole Derivatives as Novel Small Molecule Inhibitors of Neurotropic Alphaviruses. *J Infect Dis*. 2009 Apr 1; 199(7): 950-7.

Platt JL, Cascalho M, West L. Lessons from cardiac transplantation in infancy. *Pediatr Transplant*. 2009 Feb 20 (Epub ahead of print).

Ray JC, Flynn JL, Kirschner DE. Synergy between Individual TNF-Dependent Functions Determines Granuloma Performance for Controlling Mycobacterium tuberculosis Infection. *J Immunol*. 2009 Mar 15; 182(6): 3706-17.

Stapleford KA, Rapaport D, Miller DJ. Mitochondrial-Enriched Anionic Hospholipids Facilitate Flock House Virus RNA Polymerase Membrane Association. *J Virol*. 2009 Feb 25 (Epub ahead of print).

Swanson MS, Byrne BG, Dubuisson JF. Kinetic analysis of autophagosome formation and turnover in primary mouse macrophages. *Methods Enzymol*. 2009; 452: 383-402.

Taube S, Perry JW, Yetming K, Patel SP, Auble H, Shu L, Nawar HF, Lee CH, Connell TD, Shayman JA, Wobus CE. Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for Murine Noroviruses (MNV). *J Virol*. 2009 Feb 25 (Epub ahead of print).

Tkaczyk ER, Zhong CF, Ye JY, Myc A, Thomas T, Cao Z, Duran-Struuck R, Luker KE, Luker GD, Norris TB, Baker JR. In Vivo Monitoring of Multiple Circulating Cell Populations Using Two-photon Flow Cytometry. *Opt Commun*. 2008 Feb 15; 281(4): 888-894.

Neurology

Chattopadhyay M, Walter C, Mata M, Fink DJ. Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. *Brain*. 2009 Feb 24 (Epub ahead of print).

Irani DN. Cerebrospinal Fluid in Clinical Practice. Philadelphia: Saunders Elsevier; 2009.

King IL, Dickendeshler TL, Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. *Blood*. 2009 Feb 5 (Epub ahead of print).

Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. *Neurology*. 2009 Jan 27; 72(4): 337-40.

Poisson SN, Gelb DJ, Oh MF, Gruppen LD. Experience may not be the best teacher: patient logs do not correlate with clerkship performance. *Neurology*. 2009 Feb 24; 72(8): 699-704.

Neurosurgery

He Y, Hua Y, Liu W, Hu H, Keep RF, Xi G. Effects of cerebral ischemia on neuronal hemoglobin. *J Cereb Blood Flow Metab*. 2009 Mar; 29(3): 596-605.

Hua Y, Keep RF, Gu Y, Xi G. Thrombin and brain recovery after intracerebral hemorrhage. *Stroke*. 2009 Mar; 40(3 Suppl): S88-9.

Wang L, Park P, Lin CY. Characterization of stem cell attributes in human osteosarcoma cell lines. *Cancer Biol Ther*. 2009 Mar 21; 8(6) (Epub ahead of print).

Obstetrics & Gynecology

Berman DR, Mozurkewich E, Liu YQ, Barks J. Docosahexaenoic acid pretreatment confers neuroprotection in a rat model of perinatal cerebral hypoxia-ischemia. *Am J Obstet Gynecol* 2009; 200: 305.e1-305.e6.

Hultgren S, Goldstein JM, Delancey JO, Bandstra ES, Brady KT, Brown JS, Deng HW, Dunaif A, Ehrmann DA, Mayer EA, Sinha R, Tobet S, Levine JE. The vital role of ORWH. *Science*. 2009 Feb 20; 323(5917): 1009-10.

Stein TA, Kaur G, Summers A, Larson KA, DeLancey JO. Comparison of bony dimensions at the level of the pelvic floor in women with and without pelvic organ prolapse. *Am J Obstet Gynecol*. 2009 Mar; 200(3): 241.e1-5.

Xu X, Patel D A.; Dalton PK; Pearlman MD; Johnson TRB. Can Routine Neonatal Circumcision Help Prevent Human Immunodeficiency Virus Transmission in the United States? *Am J Men's Health* 2009; 3(1): 79-84.

Zheng AX, Anderson FWJ. Obstetric fistula in low-income countries. *Int J Gynecol Obstet* 2009; 104: 85-89.

Ophthalmology & Visual Sciences

Calinescu AA, Vihtelic TS, Hyde DR, Hitchcock PF. Cellular expression of midkine-a and midkine-b during retinal development and photoreceptor regeneration in zebrafish. *J Comp Neurol* 2009; 514(2): spc1.

Ishizaki E, Fukumoto M, Puro DG. Functional KATP channels in the rat retinal microvasculature: topographical distribution, redox regulation, spermine modulation and diabetic alteration. *J Physiol*. 2009 (Epub ahead of print).

Kahana A, Lucarelli MJ. Adjunctive transcanthotomy lateral suborbicularis fat lift and orbitomalar ligament resuspension in lower eyelid ectropion repair. *Ophthalm Plast Reconstr Surg* 2009; 25(1): 1-6.

Koreen IV, Cho RI, Frueh BR, Elner VM. Primary cutaneous anaplastic large cell lymphoma of the medial canthus and orbit. *Ophthalm Plast Reconstr Surg* 2009; 25(1): 63-5.

Orthopaedic Surgery

Doro LC, Ladd B, Hughes RE, Chenevert TL. Validation of an adapted MRI pulse sequence for quantification of fatty infiltration in muscle. *Magn Reson Imaging*. 2009 Mar 3 (Epub ahead of print).

Kreider JM, Goldstein SA. Trabecular Bone Mechanical Properties in Patients with Fragility Fractures. *Clin Orthop Relat Res*. 2009 Feb 27 (Epub ahead of print).

Poulter GT, Garton HJ, Blakemore LC, Hensinger RN, Graziano GP, Farley FA. Mortality and morbidity associated with correction of severe cervical hyperextension. *Spine*. 2009 Feb 15; 34(4): 378-83.

Schulmerich MV, Cole JH, Kreider JM, Esmonde-White F, Dooley KA, Goldstein SA, Morris MD. Transcutaneous Raman spectroscopy of murine bone in vivo. *Appl Spectrosc*. 2009 Mar; 63(3): 286-95.

Seibert NR, Kadakia AR. Surgical management of hallux rigidus: cheilectomy and osteotomy (phalanx and metatarsal). *Foot Ankle Clin*. 2009 Mar; 14(1): 9-22.

Otolaryngology

De Maria S, Pannone G, Bufo P, Santoro A, Serpico R, Metafora S, Rubini C, Pasquali D, Papagerakis SM, Staibano S, De Rosa G, Farina E, Emanuelli M, Santarelli A, Mariggio MA, Lo Russo L, Lo Muzio L. Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. *J Cancer Res Clin Oncol*. 2009 Jan; 135(1): 107-16.

Pathology

Choi YE, Butterworth M, Malladi S, Duckett CS, Cohen GM, Bratton SB. The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspases-3 and -7 via unique mechanisms at distinct steps in their processing. *J Biol Chem*. 2009 Mar 3 (Epub ahead of print).

Csomas RA, Wright CW, Galbán S, Oetjen KA, Duckett CS. Two distinct signalling cascades target the NF-kappaB regulatory factor c-IAP1 for degradation. *Biochem J*. 2009 Feb 25 (Epub ahead of print).

Gomez C, Bai L, Zhang J, Nikolovska-Coleska Z, Chen J, Yi H, Wang S. Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. *Bioorg Med Chem Lett*. 2009 Mar 15; 19(6): 1733-6.

Goudreault M, D'Ambrosio LM, Kean MJ, Mullin MJ, Larsen BG, Sanchez A, Chaudhry S, Chen GI, Sicheri F, Nesvizhskii AI, Aebersold R, Raught B, Gingras AC. A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. *Mol Cell Proteomics*. 2009 Jan; 8(1): 157-71.

Lunney JK, Ho CS, Wysocki M, Smith DM. Molecular genetics of the swine major histocompatibility complex, the SLA complex. *Dev Comp Immunol*. 2009 Mar; 33(3): 362-74.

Rowe RG, Li XY, Hu Y, Saunders TL, Virtanen I, Garcia de Herreros A, Becker KF, Ingvarsen S, Engelholm LH, Bommer GT, Fearon ER, Weiss SJ. Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. *J Cell Biol*. 2009 Feb 9; 184(3): 399-408.

Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma. *J Thorac Oncol*. 2009 Feb 23 (Epub ahead of print).

Sisson JC, Dewaraja YK, Wizauer EJ, Giordano TJ, Avram AM. Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine. *Thyroid*. 2009 Mar; 19(3): 297-303.

Sun W, Nikolovska-Coleska Z, Qin D, Sun H, Yang CY, Bai L, Qiu S, Wang Y, Ma D, Wang S. Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. *J Med Chem*. 2009 Feb 12; 52(3): 593-6.

Yang J, Schall C, Smith D, Kreuser L, Zamberlan M, King K, Gajarski R. HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of Luminex. *J Heart Lung Transplant*. 2009 Feb; 28(2): 123-9.

Pediatrics & Communicable Diseases

Arlt MF, Mülle JG, Schaibley VM, Ragland RL, Durkin SG, Warren St, Glover TW. Replication stress induces genome-wide copy number changes in human cells that resemble polymorphic and pathogenic variants. *Am J Hum Genet*. 2009 Mar; 84(3): 339-50.

Boxer LA. Long-lived life: a detriment. *Blood*. 2009 Feb 26; 113(9): 2047-55.

Cornell TT, Hinkovska-Galcheva V, Sun L, Cai Q, Hershenson MB, Vanway S, Shanley TP. Ceramide-dependent PP2A regulation of TNF- α induced IL-8 production in respiratory epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2009 Mar 13 (Epub ahead of print).

Dempsey AF, Cowan AE, Broder KR, Kretsinger K, Stokley S, Clark SJ. Diagnosis and testing practices for adolescent pertussis among a national sample of primary care physicians. *Prev Med*. 2009 Mar 3 (Epub ahead of print).

Dunham KM, Singer D, Freed GL. Use of board certification in ambulatory surgery center credentialing: a pilot study. *J. Healthc Manag*. 2009 Jan-Feb; 54(1): 31-42; discussion 42-3.

Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. *Lancet*. 2009 Mar 11 (Epub ahead of print).

Hanauer DA, Englesbe MJ, Cowan JA Jr, Campbell DA. Informatics and the American College of Surgeons National Surgical Quality Improvement Program: automated processes could replace manual record review. *J Am Coll Surg*. 2009 Jan; 208(1): 37-41.

Hildebrandt F, Heeringa SF. Specific podocin mutations determine age of onset of nephritic syndrome all the way into adult life. *Kidney Int*. 2009 Apr; 75(7): 669-71.

Layman WS, McEwen DP, Beyer LA, Lalani SR, Fernbach SD, Oh E, Swaroop A, Hegg CC, Raphael Y, Martens JR, Martin DM. Defects in neural stem cell proliferation and olfaction in Chd7 deficient mice indicate a mechanism for hyposmia in human CHARGE syndrome. *Hum Mol Genet*. 2009 Mar 11 (Epub ahead of print).

Macy ML, Stanley RM, Lozon MM, Sasson C, Gebremariam A, Davis MM. Trends in high-turnover stays among children hospitalized in the United States 1993-2003. *Pediatrics*. 2009 Mar; 123(3): 996-1002.

Roy S, Raskin L, Raymond VM, Thibodeau SN, Mody RJ, Gruber SB. Pediatric duodenal cancer and biallelic mismatch repair gene mutations. *Pediatr Blood Cancer*. 2009 Mar 12 (Epub ahead of print).

Sarkar S, Bhagat I, Dechert R, Schumacher RE, Donn SM. Severe intraventricular hemorrhage in preterm infants: comparison of risk factors and short-term neonatal morbidities between Grade 3 and Grade 4 intraventricular hemorrhage. *Am J Perinatol*. 2009 Mar 6 (Epub ahead of print).

Tsai WC, Hershenson MB, Zhou Y, Sajjan U. Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. *Inflamm Res*. 2009 Mar 7 (Epub ahead of print).

Psychiatry

Chen H, Wang N, Burmeister M, McInnis MG. MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. *Int J Neuropsychopharmacol*. 2009 Mar 2: 1-7 (Epub ahead of print).

Cunningham RM, Murray R, Walton MA, Chermack ST, Wojnar M, Wozniak P, Booth BM, Blow FC. Prevalence of Past Year Assault Among Inner-City Emergency Department Patients. *Ann Emerg Med*. 2009 Mar 10 (Epub ahead of print).

Husain MM, Rush JA, Wisniewski SR, McClintock SM, Fava M, Nierenberg AA, Davis L, Balasubramani GK, Young E, Alcala AA, Trivedi MH. Family history of depression and therapeutic outcome: findings from STAR*D. *J Clin Psychiatry*. 2009; 70: 185-95.

Keaton D, Lamkin N, Cassidy KA, Meyer WJ, Ignacio RV, Aulakh L, Blow FC, Sajatovic M. Utilization of herbal and nutritional compounds among older adults with bipolar disorder and with major depression. *Int J Geriatr Psychiatry*. 2009 Mar 9 (Epub ahead of print).

Lane RD, Waldstein SR, Chesney MA, Jennings JR, Lovallo WR, Kozel PJ, Rose RM, Drossman DA, Schneiderman N, Thayer JF, Cameron OG. The rebirth of neuroscience in psychosomatic medicine, part I: Historical context, methods, and relevant basic science. *Psychosom Med*. 2009 Feb; 71(2): 117-134.

Lane RD, Waldstein SR, Critchley HD, Derbyshire SWG, Drossman DA, Wager TD, Schneiderman N, Chesney MA, Jennings JR, Lovallo WR, Rose RM, Thayer JF, Cameron OG. The rebirth of neuroscience in psychosomatic medicine, part II: Clinical applications and implications for research. *Psychosom Med*. 2009 Feb; 71(2): 135-151.

Li MD, Burmeister M. New insights into the genetics of addiction. *Nat Rev Genet*. 2009 Feb 24 (Epub ahead of print).

McCarthy JF, Valenstein M, Kim HM, Ilgen M, Zivin K, Blow FC. Suicide Mortality Among Patients Receiving Care in the Veterans Health Administration Health System. *Am J Epidemiol*. 2009 Feb 27 (Epub ahead of print).

Nesse RM, Ellsworth PC. Evolution, emotions, and emotional disorders. *Am Psychol*. 2009 Feb-Mar; 64(2): 129-39.

Sajatovic M, Ignacio RV, West JA, Cassidy KA, Safavi R, Kilbourne AM, Blow FC. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. *Compr Psychiatry*. 2009 March - April; 50(2): 100-107.

Wright SL, Langenecker SA, Deldin PJ, Rapport LJ, Nielson KA, Kade AM, Own LS, Akil H, Young EA, Zubieta JK. Gender-specific disruptions in emotion processing in younger adults with depression. *Depress Anxiety*. 2009; 26(2): 182-9.

Young EA, Kornstein SG, Marcus SM, Harvey AT, Warden D, Wisniewski SR, Balasubramani GK, Fava M, Trivedi MH, John Rush A. Sex differences in response to citalopram: A STAR *D report. *J Psychiatr Res*. 2009 Feb; 43(5): 503-11.

Zivin K, Pfeiffer P, McCammon RJ, Kavanagh J, Walters H, Welsh D, Difranco D, Brown, M. Valenstein, M. No-shows: who fails to follow-up with initial behavioral health appointments? *American Journal of Managed Care*. 2009; 15(2): 105-112.

Zubieta JK, Stohler CC. Neurobiological Mechanisms of Placebo Responses. In: *The Year in Cognitive Neuroscience 2009*, Annals of The New York Academy of Sciences, March 2009.

Radiation Oncology

Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. *J Clin Endocrinol Metab*. 2009 Jan; 94(1): 204-12.

Cao Y, Tsien CI, Sundgren PC, Nagesh V, Normolle D, Buchtel H, Junck L, Lawrence TS. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for prediction of radiation-induced neurocognitive dysfunction. *Clin Cancer Res*. 2009 Mar 1; 15(5): 1747-54.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. *J Natl Compr Canc Netw*. 2009 Feb; 7(2): 122-92.

Derheimer F, Hicks K, Paulsen MT, Canman C and Ljungman M. Psoralen-induced interstrand DNA cross-links block transcription and induce p53 in an ATR-dependent manner. *Mol Phar* 2009; 75: 599-607.

Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. *Int J Radiat Oncol Biol Phys*. 2009 Mar 15; 73(4): 1228-34.

Gluck J, Vineberg KA, Ten Haken RK, Sandler HM. Evaluating the relationships between rectal normal tissue complication probability and the portion of seminal vesicles included in the clinical target volume in intensity-modulated radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2009 Feb 1; 73(2): 334-40.

Gonzalez ME, Li X, Toy K, DuPrie M, Ventura A, Banerjee M, Ljungman M, Merajver SD and Kleer CG. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA-1. *Oncogene* 2009; 28: 843-53.

Jagsi R, Abrahamse P, Morrow M, Griggs JJ, Schwartz K, Katz SJ. Postmastectomy radiotherapy for breast cancer: patterns, correlates, communication, and insights into the decision process. *Cancer*. 2009 Mar 15; 115(6): 1185-93.

Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J, Ten Haken RK, Lawrence TS, Cao Y, Tsien C. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. *Int J Radiat Oncol Biol Phys*. 2009 Feb 1; 73(2): 479-85.

Li XA, Tai A, Arthur DW, Buchholz TA, Macdonald S, Marks LB, Moran JM, Pierce LJ, Rabinovitch R, Taghian A, Vicini F, Woodward W, White JR; Radiation Therapy Oncology Group Multi-Institutional and Multiobserver Study. Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. *Int J Radiat Oncol Biol Phys*. 2009 Mar 1; 73(3): 944-51.

Rosenzweig KE, Movsas B, Bradley J, Gewanter RM, Gopal RS, Komaki RU, Kong FM, Lee HK, Feins RH, Langer CJ. ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. *J Am Coll Radiol*. 2009 Feb; 6(2): 85-95.

Sabel MS, Rogers K, Griffith K, Jagsi R, Kleer CG, Diehl KA, Breslin TM, Cimmino VM, Chang AE, Newman LA. Residual disease after re-excision lumpectomy for close margins. *J Surg Oncol*. 2009 Feb 1; 99(2): 99-103.

Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. *AJR Am J Roentgenol*. 2009 Feb; 192(2): W45-52.

Sundgren PC, Nagesh V, Elias A, Tsien C, Junck L, Gomez Hassan DM, Lawrence TS, Chenevert TL, Rogers L, McKeever P, Cao Y. Metabolic alterations: a biomarker for radiation-induced normal brain injury--an MR spectroscopy study. *J Magn Reson Imaging*. 2009 Feb; 29(2): 291-7.

Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M, Simeone DM. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. *Cancer Cell*. 2009 Mar 3; 15(3): 207-19.

Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL; American Society of Clinical Oncology. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. *J Clin Oncol*. 2009 Feb 10; 27(5): 812-26.

Wu J, Huen MS, Lu LY, Ye L, Dou Y, Ljungman M, Chen J and Yu X. Histone ubiquitination associated with BRCA-1 dependent DNA damages response. *Mol Cell* 2009; 29: 849-60.

Zeng ZZ, Yao H, Staszewski ED, Rockwood KF, Markwart SM, Fay KS, Spalding AC, Livant DL. alpha(5)beta(1) Integrin Ligand PHSRN Induces Invasion and alpha(5) mRNA in Endothelial Cells to Stimulate Angiogenesis. *Transl Oncol*. 2009 Mar; 2(1): 8-20.

Radiology

Miller DL, Dou C, Induction of Apoptosis in Sonoporation and Ultrasonic Gene Transfer. *Ultrasound Med Biol*. 2009; 35: 144-54.

Samuel S, Fowlkes JB, and Miller DL. An In Vitro Study of the Correlation Between Bubble Distribution, Acoustic Emission, and Cell Damage by Contrast Ultrasound. *IEEE Trans UFFC*. 2009; 56: 589-599.

Sinha SP, Narayanan R, Ma B, Roubidoux MA, Liu H, and Carson PL, Image Registration for Detection and Quantification of Change on Digital Tomosynthesis Mammographic Volumes. *Am J Roentgenol*. 2009; 192: 384-387.

Surgery

General Surgery:

Kheterpal S, Tremper KK, Heung M, Rosenberg AL, Englesbe M, Shanks AM, Campbell DA, Jr. Development and validation of an acute kidney injury risk index for patients undergoing general surgery: Results from a national dataset. *Anesthesiology* 2009; 110(3): 505-515.

Urology

Clemens JQ, Markossian T, Calhoun EA. Comparison of Economic Impact of Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Interstitial Cystitis/Painful Bladder Syndrome. *Urology*. 2009 Feb 2 (Epub ahead of print).

Grubb R, Deng J, Pinto P, Mohler J, Chinnaiyan A, Rubin M, Linehan W, Liotta L, Petricoin E, Wulfkuehle J. Pathway Biomarker Profiling of Localized and Metastatic Human Prostate Cancer Reveal Metastatic and Prognostic Signatures. *J Proteome Res*. 2009 Mar 10 (Epub ahead of print).

Heidelbaugh JJ. Foreword. The 36th year of existence for Primary Care. *Prim Care*. 2009 Mar; 36(1): xiii-xiv.

Heidelbaugh JJ, Biggs WS. Preface. A greater awareness of women's health issues. *Prim Care*. 2009 Mar; 36(1): xv-xvi.

Huang H. Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109. *Urol Oncol*. 2009 Mar-Apr; 27(2): 230.

Lewicky-Gaup C, McGuire EJ, Fenner DE. Multiple perineal abscesses and sinus tracts as a complication of vaginal mesh. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Feb 20 (Epub ahead of print).

Lucas N, Day ML. The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression. *J Cell Biochem*. 2009 Feb 19; 106(6): 967-974.

McCullough PA, Chinnaiyan KM. Hazards of contrast-induced acute kidney injury in elderly women. *Womens Health (Lond Engl)*. 2009 Mar; 5(2): 123-5.

Ohl DA, Quallich SA, Sønksen J, Brackett NL, Lynne CM. Anejaculation: an electrifying approach. *Semin Reprod Med*. 2009 Mar; 27(2): 179-85.

Prensner JR, Chinnaiyan AM. Oncogenic gene fusions in epithelial carcinomas. *Curr Opin Genet Dev*. 2009 Feb; 19(1): 82-91.

Ray AM, Zuhlke KA, Levin AM, Douglas JA, Cooney KA, Petros JA. Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. *Prostate*. 2009 Mar 6 (Epub ahead of print).

Schwarzer M, Faerber G, Rueckauer T, Blum D, Pytel G, Mohr FW, Doentz T. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo. *Basic Res Cardiol*. 2009 Mar 14 (Epub ahead of print).

Wang R, Faerber GJ, Roberts WW, Morris DS, Wolf JS Jr. Single-Center North American Experience With Wolf Piezolith 3000 in Management of Urinary Calculi. *Urology*. 2009 Mar 9 (Epub ahead of print).

Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ, Raz A. Regulation of Prostate Cancer Progression by Galectin-3. *Am J Pathol*. 2009 Mar 12 (Epub ahead of print).

Yocum AK, Chinnaiyan AM. Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. *Brief Funct Genomic Proteomic*. 2009 Mar 11 (Epub ahead of print).